PharmiWeb.com - Global Pharma News & Resources
04-Feb-2021

Enzyme Linked Immunosorbent Assay (ELISA) Market is expected to reach US$ 2.3 Billion With CAGR of Approx 5.1 % By 2025

Global Enzyme-linked Immunosorbent Assay (ELISA) Market – Insights

Enzyme-linked Immunosorbent Assay (ELISA) is a commonly used analytical biochemistry assay, used to identify proteins, peptides, antibodies, and hormones. ELISA is used in various fields such as biotechnology, pharmaceuticals, and medical diagnosis that include HIV infection, pregnancy tests, and measurement of cytokines, soluble proteins, and others. ELISA is also used to measure enzyme activity. In the field of toxicology, ELISA can be used to determine certain classes of drugs. Various antigen-antibody combinations are used in the immunoassay that include an enzyme-labeled antigen or antibody. Depending on the antigen-antibody combination, ELISA can be divided into direct ELISA, indirect ELISA, sandwich ELISA, and competitive ELISA.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/1505

The global Enzyme-linked Immunosorbent Assay (ELISA) market was valued at US$ 1,583.4 million in 2017 and is expected to witness a robust CAGR of 5.1% over the forecast period (2017 – 2025).

Figure 1. Global Enzyme Linked Immunosorbent Assay (ELISA) Market in (US$ Mn), by Region, 2017

Source: Coherent Market Insights (2018)

Global Enzyme-linked Immunosorbent Assay (ELISA) Market: Drivers  

High incidence of infectious disease such as HIV and growing awareness regarding diagnosis of cancer and autoimmune diseases is a major factor boosting growth of the global enzyme-linked immunosorbent assay market. For instance, according to the Centers for Disease Control & Prevention (CDC), 2014, the number of patients infected with HIV in the U.S. was 37,600. Moreover, the CDC reported a decline of 10% in the incidence rate of HIV as compared to 2010, owing to early detection and advanced diagnostic.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1505

Increasing prevalence of infectious diseases and cancer and high demand for cost-effective diagnostic tools is also expected to boost growth of the market. For instance, according to the CDC, 2015, the number of visits to physician offices for infectious and parasitic diseases in the U.S. was 16.8 million. Moreover, high incidence of vector borne diseases is also expected to boost growth of the market. For instance, according to the World Health Organization (WHO), 2017, vector borne diseases account for over 17% of all infectious diseases causing over 700,000 deaths worldwide, annually. Dengue is most commonly occurring vector borne disease with around 96 million new cases diagnosed, annually.

Increasing R&D in ELISA is expected to contribute to growth of the global enzyme-linked immunosorbent assay market over the forecast period. For instance, in August 2017, researchers at University of Illinois, Urbana Campaign, developed a portable spectral analyzer based on ELISA assay that enables a smartphone to perform lab grade medical diagnostic tests, which usually requires expensive instruments. This test includes detection and measurement of variety of proteins and antibodies in blood, urine, and saliva samples that is commonly used for wide range of clinical diagnostic tests.

Global Enzyme-linked Immunosorbent Assay (ELISA) Market: Restraints   

ELISA is prone to cross reactivity, which may lead to false positive or false negative results. Such drawback is expected to hinder growth of the global enzyme-linked immunosorbent assay market. For instance, according to study published by American Medical Association in 2011, the preliminary health department data identified 32 pregnant women with HIV positive through ELISA. However, after a confirmatory test, 17 of these women were confirmed to be negative for HIV virus.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/enzyme-linked-immunosorbent-assay-elisa-market-to-surpass-well-beyond-us-23-billion-by-2025-833

Global Enzyme-linked Immunosorbent Assay (ELISA) Market: Regional Analysis   

On the basis of region, the global enzyme-linked immunosorbent assay market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to account for the largest market share in the global enzyme-linked immunosorbent assay market, owing to increasing launch of novel products in the region. For instance, in January 2018, Eagle Biosciences, Inc. introduced a novel intact FGF23 ELISA kit assay— a 96 well Sandwich ELISA that measures the full length active form of Human Intact FGF23 used for the detection of mineral bone disorder, chronic kidney disease, tumor induced osteomalacia, and hyperphosphatemia. Moreover, in March 2018, BARD1 Life Sciences, a U.S-based science research company, was expected to commercialize its BARD1-Ovarian blood based ELISA test to identify ovarian cancer in early stages.

Increasing focus of regional market players to expand their geographical presence is expected to boost growth of the market in Asia Pacific. For instance, in January 2017, Fujirebio, a Japan-based IVD diagnostic testing company, introduced Lumipulse G β-Amyloid 1-42 ELISA assay in Europe that facilitates quantitative measurement of β-amyloid1-42 in human cerebrospinal fluid within of 30 minutes.

Global Enzyme-linked Immunosorbent Assay (ELISA) Market: Competitive Landscape   

Major players in the market are focused on adopting product development strategies to expand their product portfolio. For instance, in January 2017 Illumina, Inc. and BioRad Laboratories, Inc. introduced the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis that aids researchers to assess the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic responses. Moreover, in 2015, Enzo Life Sciences introduced new VEGF ELISA Kit, an ultra-sensitive assay as competitive detection method for measuring VEGF in serum, plasma, and cell culture supernatants that measures as little as 4 pg /ml of VEGF and provides quantitative results.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1505

Major players operating the global enzyme-linked immunosorbent assay market include, Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., and Shenzhen YHLO Biotech Co., Ltd.

Detailed Segmentation:

  • Global Enzyme-Linked Immunosorbent Assay (ELISA) Market, By Method:
    • Direct ELISA
    • Indirect ELISA
    • Sandwich ELISA
    • Competitive ELISA
  • Global Enzyme-Linked Immunosorbent Assay (ELISA) Market, By Application:
    • Vaccine Development
    • Immunology
    • Diagnostics
    • Toxicology
    • Drug Monitoring & Pharmaceutical Industry
    • Transplantation
  • Global Enzyme-Linked Immunosorbent Assay (ELISA) Market, By Technology:
    • Chemiluminescent
    • Colorimetric
    • Fluorescent
  • Global Enzyme-Linked Immunosorbent Assay (ELISA) Market, By Geography:
    • By Method:
      • Direct ELISA
      • Indirect ELISA
      • Sandwich ELISA
      • Competitive ELISA
    • By Application:
      • Vaccine Development
      • Immunology
      • Diagnostics
      • Toxicology
      • Drug Monitoring & Pharmaceutical Industry
      • Transplantation
    • By Technology:
      • Chemiluminescent
      • Colorimetric
      • Fluorescent
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 04-Feb-2021